AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a ...

AstraZeneca executives say they are “not worried” that the failure of tozorakimab in a phase 2 chronic obstructive pulmonary ...

has approved the clinical trial protocol amendment proposal of the drug major AstraZeneca Pharma India to study the long-term efficacy and safety of Tozorakimab in participants with chronic ...

Carillon Eagle Growth & Income Fund highlighted stocks like AstraZeneca PLC (NASDAQ:AZN) in the second quarter 2024 investor letter. AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other 52-week high stocks. The U.S. stock market has been on a roll, with major indices ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The strong replenishment of new drugs ...

AstraZeneca has beaten all healthcare-focused ETFs. The stock is up by over 27% this year, helped by its oncology business. It has gotten highly overbought, meaning that a pullback is coming ...

Chris Nemeth, 51, worked in airline logistics until he got the AstraZeneca vaccine in July 2021 and developed chronic inflammatory demyelinating polyneuropathy (CIPD) which can cause numbness ...

Tozorakimab is under clinical development by AstraZeneca and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) ...

Tozorakimab is under clinical development by AstraZeneca and currently in Phase II for Chronic Bronchitis. According to GlobalData, Phase II drugs for Chronic Bronchitis have a 77% phase transition ...